Publikationen
2011
- Gaidzik VI, Bullinger L, Schlenk RF, Zimmermann AS, Röck J, Paschka P, Corbacioglu A, Krauter J, Schlegelberger B, Ganser A, Späth D, Kündgen A, Schmidt-Wolf IGH, Götze K, Nachbaur D, Pfreundschuh M, Horst HA, Döhner H, Döhner K:
RUNX1 mutations in acute myeloid leukemia: Results from a comprehensive genetic and clinical analysis on 945 Patients from the AML Study Group (AMLSG). J Clin Oncol. 2011 Apr 1; 29(10):1364-72.
- Damm F, Oberacker T, Thol F, Surdziel E, Wagner K, Chaturvedi A, Morgan M, Bomm K, Göhring G, Lübbert M, Kanz L, Fiedler W, Schlegelberger B, Heil G, Schlenk RF, Döhner K, Döhner H, Krauter J, Ganser A, and Heuser M:
Prognostic importance of histone methyltransferase Mixed Lineage Leukemia 5 (MLL5) expression in acute myeloid leukemia. J Clin Oncol. 2011 Feb 20; 29(6):682-9.
- Marcucci G, Haferlach T, Döhner H: Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications. J Clin Oncol. 2011 Feb 10; 29(5):475-86.
- Hehlmann R, Grimwade D, Simonsson B, Apperley J, Baccarani M, Barbui T, Barosi G, Bassan R, Bene' MC, Berger U, Buchner T, Burnett A, Cross N, De Witte T, Dohner H, Dombret H, Einsele H, Engelich G, Foa' R, Fonatsch C, Goekbuget N, Gluckman E, Gratwohl A, Guilhot F, Haferlach C, Haferlach T, Hallek M, Hasford J, Hochhaus A, Hoelzer D, Kiladjian JJ, Labar B, Ljungman P, Mansman U, Niederwieser D, Ossenkoppele G, Ribera JM, Rieder H, Serve H, Schrotz-King P, Sanz MA, Sausele S:
The European LeukemiaNet - Achievements and perspectives. Haematologica. 2011 Jan; 96(1):156-62.
2010
- Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P,
Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M,
Sierra J, Tallman MS, Löwenberg B, Bloomfield CD. Diagnosis and management of acute
myeloid leukemia in adults: recommendations from an International Expert Panel, on behalf of
the European LeukemiaNet. Blood. 2010; 115(3):453-474.
- Damm F, Heuser M, Morgan M, Yun H, Großhennig A, Göhring G, Schlegelberger B, Döhner K,
Ottmann O, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H,
Döhner H, Heil G, Ganser A, Krauter J. Single nucleotide polymorphism in the mutational hotspot
of WT1 predicts a favourable outcome in cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2010; 28(4):578-85.
- Gröschel S,* Lugthart S,* Schlenk RF, Valk PJM, Eiwen K, Goudswaard C, van Putten WJL, Kayser S, Verdonck LF, Lübbert M, Ossenkoppele GJ, Germing U, Schmidt-Wolf I, Schlegelberger
B, Krauter J, Ganser A, Döhner H, Löwenberg B, Döhner K,* Delwel R.* High EVI1 expression
predicts outcome in younger adult patients with acute myeloid leukemia and is associated with
distinct cytogenetic abnormalities. J Clin Oncol. 2010; 28(12):2101-7. *Equal contribution
- Wagner K, Damm F, Göhring G, Görlich K, Heuser M, Schäfer I, Ottmann O, Lübbert M, Heit W,
Kanz L, Schlimok G, Raghavachar AA, Fiedler W, Kirchner HH, Brugger W, Zucknick M,
Schelgelberger B, Heil G, Ganser A, Krauter J. Impact of IDH1 R132 mutations and an IDH1
single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP
rs11554137 is an adverse prognostic factor. J Clin Oncol. 2010 May 10; 28(14):2356-64.
- Thol F, Damm F, Wagner K, Göhring G, Schlegelberger B, Hoelzer D, Lübbert M, Heit W, Kanz
L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Heil G, Heuser M, Krauter J, Ganser A.
Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood. 2010 Jul 29; 116(4):614-6.
- Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S,
Zucknick M, Götze K, Horst HA, Germing U, Döhner H, Döhner K. IDH1 and IDH2 mutations are
frequent genetic alterations in acute myeloid leukemia (AML) and confer adverse prognosis in
cytogenetically normal AML with NPM1 mutation without FLT3-ITD. J Clin Oncol. 2010 Aug 1; 28(22):3636-43.
- Lugthart S,* Gröschel S,* Beverloo HB, Kayser S, Valk PJM, van Zelderen-Bhola SL, Ossen-
koppele GJ, Vellenga E, van den Berg-de Ruiter E, Schanz U, Verhoel G, Ferrant A, Köhne CH,
Pfreundschuh M, Horst HA, Koller E, von Lilienfeld-Toal M, Bentz M, Ganser A, Schlegelberger
B, Jotterand M, Krauter J, Pabst T, Theobald M, Schlenk RF, Delwel R, Döhner K, Löwenberg B,*
Döhner H.* Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/
t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia: A study in
6,500 cases of AML. J Clin Oncol. 2010 Aug 20; 28(24):3890-8. *Equal contribution
- Corbacioglu A,* Scholl C,* Schlenk RF, Eiwen K, Du J, Bullinger L, Fröhling S, Reimer P,
Rummel M, Derigs HG, Nachbaur D, Krauter J, Ganser A, Döhner H, Döhner K, for the German-
Austrian AML Study Group (AMLSG). Prognostic impact of minimal residual disease in CBFB-
MYH11-positive acute myeloid leukemia. J Clin Oncol. 2010 Aug 10; 28(23):3724-9. *Equal contribution
- Schlenk RF, Döhner K, Mack S, Stoppel M, Király F, Götze K, Hartmann F, Horst HA, Koller E, Petzer A, Grimminger W, Kobbe G, Glasmacher A, Salwender H, Kirchen H, Haase D, Kremers S, Matzdorff A, Benner A, Döhner H:
Prospective Evaluation of Allogeneic Hematopoietic Stem-Cell Transplantation From Matched Related and Matched Unrelated Donors in Younger Adults With High-Risk Acute Myeloid Leukemia: German-Austrian Trial AMLHD98A.J Clin Oncol. 2010 Oct 20;28(30):4642-8.
- Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Maertens J, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, van Marwijk Kooy M, Verdonck LF, Beck J, Döhner H, Gratwohl A, Pabst T, Verhoef G; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON); German AML Study Group (AMLSG); Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group:
High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009 Sep 24;361(13):1235-48.
- Kayser S, Schlenk RF, Correa Londono M, Breitenbuecher F, Wittke K, Du J, Groner S, Späth D, Krauter J, Ganser A, Döhner H, Fischer T, Döhner K for the German-Austrian AML Study Group (AMLSG):
Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood. 2009 Sep 17;114(12):2386-92.
- Kayser S and Schlenk RF:
New drugs in the treatment of acute myeloid leukemia. Memo. 2009 Juni;2:75-79.
- Koreth J, Schlenk RF, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo DJ, Stone RM, Sakamaki H, Appelbaum FR, Döhner H, Antin JH, Soiffer RJ, Cutler C:
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: a systematic review and meta-analysis of 24 prospective clinical trials. JAMA. 2009 June 10;301(22): 2349-61.
- Krauter J, Wagner K, Schäfer I, Marschalek R, Meyer C, Heil G, Schaich M, Ehninger G, Niederwieser D, Krahl R, Büchner T, Sauerland C, Schlegelberger B, Döhner K, Döhner H, Schlenk R, Ganser A:
Prognostic factors in adult patients up to 60 years with AML and translocations of chromosome band 11q23: Individual patient data meta-analysis of the German AML Intergroup. J Clin Oncol. 2009 May 4; 2009;27:3000-3006.
- Gaidzik VI, Schlenk RF, Moschny S, Becker A, Bullinger L, Corbacioglu A, Krauter J, Schlegelberger B, Ganser A, Döhner H, and Döhner K, for the German-Austrian AML Study Group (AMLSG):
Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia (AML): A Study of the German-Austrian AML Study Group (AMLSG). Blood. 2009 May 7;113(19):4505-11.
- Kayser S and Schlenk RF:
Tailored therapeutic approaches in acute myeloid leukemia. Memo. 2009 März; 2(Suppl 1):18-21.
- Schlenk RF and Döhner K:
Impact of new prognostic markers in treatment decisions in acute myeloid leukemia. Curr Opin Hematol. 2009 Mar;16(2):98-104.
- Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Büchner T, Döhner H, Burnett AK, Lo-Coco F:
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009 Feb 26;113(9):1875-91.
- Schlenk RF, Döhner K, Kneba M, Götze K, Hartmann F, del Valle F, Kirchen H, Koller E, Fischer JT, Bullinger L, Habdank M, Späth D, Groner S, Krebs B, Kayser S, Corbacioglu A, Anhalt A, Benner A, Fröhling S, Döhner H, for the German-Austrian AML Study Group (AMLSG):
Gene Mutations and Response to Treatment with All-Trans Retinoic Acid in Elderly Patients with Acute Myeloid Leukemia – Results from AMLSG Trial AML HD98B. Haematologica. 2009 Jan;94(1):54-60.
- Messerer D, Engel J, Hasford J, Schaich M, Ehninger G, Sauerland C, Büchner T, Schumacher A, Krahl R, Niederwieser D, Krauter J, Ganser A, Creutzig U, Döhner H, Schlenk RF for the German AML Intergroup:
Impact of Different Postremission Strategies on Quality-of-Life in Acute Myeloid Leukemia Patients. Haematologica , 2008 Jun;93(6):826-33.
- Liso A, Castiglione F, Cappuccio A, Stracci F, Schlenk RF, Amadori S, Thiede C, Schnittger S, Valk PJ, Döhner K, Martelli MF, Schaich M, Krauter J, Ganser A, Martelli MP, Bolli N, Löwenberg B, Haferlach T, Ehninger G, Mandelli F, Döhner H, Michor F, Falini B:
A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1). Haematologica. 2008 Aug;93(8):1219-26.
- Schlenk RF*, Döhner K*, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H; German-Austrian Acute Myeloid Leukemia Study Group:
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008 May 1;358(18):1909-18. (*equal contribution).
- Schlenk RF, Pasquini M, Pérez WS, Zhang MJ, Krauter J, Antin JH, Bashey A, Bolwell BJ, Büchner T, Cahn JY, Cairo MS, Copelan EA, Cutler CS, Döhner H, Gale RP, Ilhan O, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Nimer SD, Sierra S, Tallman MS, Weisdorf DJ, Horowitz MM, Ganser A, CIBMTR Acute Leukemia Working Committee:
HLA-Identical Sibling Allogeneic Transplants versus Chemotherapy in Acute Myelogenous Leukemia with t(8;21) in First Complete Remission: Collaborative Study between the German AML Intergroup and CIBMTR. Biol Blood Marrow Transplant 2008 Feb;14(2);14:187-196.
- Creutzig U, Büchner T, Sauerland MC, Zimmermann M, Reinhardt D, Döhner H, Schlenk RF:
Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Cancer. 2008 Feb 1;112(3):562-71.
- Heuser M, Argiropoulos B, Kuchenbauer F, Yung E, Piper J, Fung S, Schlenk RF, Döhner K, Rudolph C, Schambach A, Baum C, Schlegelberger B, Döhner H, Ganser A, Humphries RK:
MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in AML patients. Blood. 2007 Sep 1;110(5):1639-47.
- Fröhling S, Schlenk RF, Kayser S, Morhardt M, Benner A, Döhner K, Döhner H.
Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood. 2006 Nov 15;108(10):3280-8.
- Schlenk RF, Fröhling S, Hartmann F, Fischer JTh, Glasmacher A, del Valle F, Götze K, Nerl C, Schoch R, Pralle H, Mergenthaler HG, Hensel M, Koller E, Kirchen H, Matzdorff A, Salwender H, Biedermann HG, Kremers S, Haase D, Benner A, Döhner K, Döhner H.
Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment trial. Leukemia. 2006 Apr;20(4):748-50.
- Döhner K, Schlenk RF, Habdank M, Scholl C, Rücker FG, Corbacioglu A, Bullinger L, Fröhling S, Döhner H for the AML Study Group (AMLSG).
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics – interaction with other gene mutations. Blood 106(12):3740-6, 2005.
- Schlenk RF, Germing U, Hartmann F, Glasmacher A, Fischer JT, del Valle y Fuentes F, Götze K, Pralle H, Nerl C, Salwender H, Grimminger W, Petzer A, Hensel M, Benner A, Zick L, Döhner K, Fröhling S, Döhner H, and the AML Study Group (AMLSG).
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia 19(6): 978-83, 2005.
Stand: September 2009
